Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot returning colorectal cancer earlier

NCT ID NCT04739072

Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing if a simple blood test can find tiny bits of tumor DNA left after treatment, which might help doctors know if colorectal cancer will return sooner than current methods. About 1,000 people with colorectal cancer who have finished or are about to start treatment will give blood samples over time. The goal is to see if these DNA signals can predict recurrence and improve follow-up care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2019

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with colorectal cancer at MD Anderson Cancer Center.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years. 2. Histological/cytological confirmation of colorectal adenocarcinoma. 3. Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy. 4. Ability to understand and the willingness to sign a written informed consent document. 5. Willing to pursue standard of care surveillance post completion of curative therapies. 6. Willing to provide blood samples for correlative research. Exclusion Criteria: 1. Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible. 2. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal adenocarcinoma Stage I colorectal cancer ajcc V8 Stage II colorectal cancer ajcc V8 Stage IIA colorectal cancer ajcc V8 Stage IIB colorectal cancer ajcc V8 Stage IIC colorectal cancer ajcc V8 Stage III colorectal cancer ajcc V8 Stage IIIA colorectal cancer ajcc V8 Stage IIIB colorectal cancer ajcc V8 Stage IIIC colorectal cancer ajcc V8 Stage IV colorectal cancer ajcc V6 Stage IVA colorectal cancer ajcc V8 Stage IVB colorectal cancer ajcc V8 Stage IVC colorectal cancer ajcc V8

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Banner - MD Anderson Cancer Center

    TERMINATED

    Gilbert, Arizona, 85234, United States

  • Baptist- MD Anderson Cancer Center

    TERMINATED

    Jacksonville, Florida, 32207, United States

  • Baylor Scott & White Research Institute

    TERMINATED

    Temple, Texas, 76508, United States

  • Cooper Hospital UNIV MED CTR.

    TERMINATED

    Camden, New Jersey, 08103, United States

  • Houston Methodist Cancer Center

    TERMINATED

    Houston, Texas, 77030, United States

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • St. Luke's Cancer Institute

    TERMINATED

    Boise, Idaho, 83712, United States

  • The Queen's Medical Center

    TERMINATED

    Honolulu, Hawaii, 96813, United States

  • UT Health San Antonio MD Anderson Cancer Center

    TERMINATED

    San Antonio, Texas, 78229, United States

  • UT Southwestern/Simmons Cancer Center-Dallas

    TERMINATED

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.